ReviewClinical, cosmetic and investigational dermatology2025
Mechanisms and Recent Advances of Small-Molecule Therapeutics in Rosacea Treatment.
Review in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The association between atopic dermatitis and rosacea: a comprehensive review from comorbidities to pathogenic mechanisms.Frontiers in immunology · 2026Review
- Calcitonin gene-related peptide promotes mast cell-mediated neuroimmune inflammation through the CALCRL/RAMP1-JAK3-STAT1 axis in rosacea.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rosacea is a common dermatological disease, and the complexity of its etiology and pathogenesis makes conventional treatment of rosacea difficult. Small-molecule drugs are a new option for the treatment of rosacea. Based on its good efficacy, convenience of use, affordable price and other advantages, more and more small-molecule drugs are used in the treatment and management of rosacea, involving a variety of molecular pathways, including JAK/STAT signaling pathway, TRPV, TLR2-KLK5-LL37 and mTOR pathways, Th1/Th17-IL17, PED-4, AhR and MRGPRX2. However, the specific treatment mechanism and research progress have not been systematically elucidated. This review summarizes the latest advances in small molecules targeting key inflammatory pathways in rosacea, provides new ideas for the treatment of rosacea and new directions for the clinical management of rosacea. In addition, we need to pay attention to individual differences in patients, the side effects of drugs and formulations. Therefore, further research on small-molecule drugs for the treatment of rosacea is very necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.